<unk>  is an HBV nucleoside analogue reverse transcriptase inhibitor that is FDA approved for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, increased creatine kinase (CK), headache, cough, diarrhea, abdominal pain, nausea, pharyngolaryngeal pain, arthralgia, pyrexia, rash, back pain, dizziness, myalgia, ALT increased, dyspepsia, insomnia, and abdominal distension.
Telbivudine
Lamivudine
Saquinavir
Fosamprenavir
Abacavir
Tipranavir
Letermovir
Etravirine